Skip to main content
Year archive

Hutchmed (China) Limited — 2023 filings

All 108 regulatory filings released by Hutchmed (China) Limited (HCM) in 2023, sourced directly from the official regulator.

108 Filings
2023 Period
2023 filings (108)
Filing Released Lang
6-K
Regulatory Filings
2023-12-29 English
Total Voting Rights
Regulatory Filings
2023-12-29 English
Blocklisting Six Monthly Return
Regulatory Filings
2023-12-29 English
6-K
Regulatory Filings
2023-12-21 English
Overseas Regulatory Announcement
Regulatory Filings
2023-12-21 English
6-K
Regulatory Filings
2023-12-13 English
Inclusion in National Reimbursement Drug List
Regulatory Filings
2023-12-13 English
Completed Enrollment of Phase II/III Trial
Regulatory Filings
2023-12-13 English
6-K
Regulatory Filings
2023-12-07 English
Overseas Regulatory Announcement
M&A Activity
2023-12-07 English
6-K
Regulatory Filings
2023-12-01 English
Clinical Data to be Presented at Congresses
Regulatory Filings
2023-12-01 English
6-K
Regulatory Filings
2023-11-30 English
Total Voting Rights
Regulatory Filings
2023-11-30 English
6-K
Regulatory Filings
2023-11-09 English
U.S. FDA Approval of FRUZAQLA™ (fruquintinib)
Regulatory Filings
2023-11-09 English
6-K
Regulatory Filings
2023-10-24 English
Vesting of awards under the LTIP
Director's Dealing
2023-10-24 English
6-K
Regulatory Filings
2023-10-16 English
Clinical Data to be Presented at ESMO 2023
Regulatory Filings
2023-10-16 English
6-K
Regulatory Filings
2023-09-29 English
Total Voting Rights
Regulatory Filings
2023-09-29 English
NDA Submission for Fruquintinib in Japan
Regulatory Filings
2023-09-29 English
6-K
Director's Dealing
2023-09-14 English
Director’s Share Dealing
Director's Dealing
2023-09-14 English
Regulatory Filings 2023
Regulatory Filings
2023-09-12 English
6-K
Regulatory Filings
2023-09-12 English
Phase IIIb Savolitinib Results at WCLC 2023
Regulatory Filings
2023-09-12 English
Patient Enrollment Completed for Bridging Study
Regulatory Filings
2023-09-12 English
6-K
Regulatory Filings
2023-08-31 English
Total Voting Rights
Regulatory Filings
2023-08-31 English
6-K
Regulatory Filings
2023-08-29 English
BTD in China for Savolitinib for Gastric Cancer
Regulatory Filings
2023-08-29 English
Regulatory Filings 2023
Regulatory Filings
2023-08-24 English
6-K
Regulatory Filings
2023-08-21 English
Sovleplenib Phase 3 Study Meets Primary Endpoint
Regulatory Filings
2023-08-21 English
Regulatory Filings 2023
Regulatory Filings
2023-08-10 English
6-K
Director's Dealing
2023-08-07 English
Exercise of Share Options by a Director
Director's Dealing
2023-08-07 English
FORM 6-K
Interim / Quarterly Report
2023-07-31 English
Interim Results and Business Updates
Interim / Quarterly Report H1 2023
2023-07-31 English
6-K
Regulatory Filings
2023-07-20 English
Breakthrough Therapy Designation for Fruquintinib
Regulatory Filings
2023-07-20 English
6-K
Board/Management Information
2023-07-13 English
Changes to Board and Technical Committee
Board/Management Information
2023-07-13 English
6-K
Regulatory Filings
2023-07-10 English
Phase 1 Study of HMPL-415 Initiated
Regulatory Filings
2023-07-10 English
6-K
Regulatory Filings
2023-06-29 English
Blocklisting Six Monthly Return
Regulatory Filings
2023-06-29 English
6-K
Report Publication Announcement
2023-06-26 English
HUTCHMED to Announce 2023 Half-Year Results
Report Publication Announcement
2023-06-26 English
6-K
Regulatory Filings
2023-06-16 English
Phase III FRESCO-2 Results in The Lancet
Regulatory Filings
2023-06-16 English
MAA of Fruquintinib Validated by the EMA
Regulatory Filings
2023-06-15 English
6-K
Regulatory Filings
2023-06-09 English
HUTCHMED Highlights Presentations at EHA and ICML
Regulatory Filings
2023-06-09 English
6-K
Regulatory Filings
2023-06-06 English
LTIP and Share Option Scheme
Regulatory Filings
2023-06-06 English
6-K
Declaration of Voting Results & Voting Rights Announcements
2023-05-31 English
Total Voting Rights
Regulatory Filings
2023-05-31 English
6-K
Regulatory Filings
2023-05-26 English
Fruquintinib NDA Granted Priority Review by FDA
Regulatory Filings
2023-05-26 English
HUTCHMED Highlights Presentations at ASCO 2023
Regulatory Filings
2023-05-26 English
6-K
Regulatory Filings
2023-05-17 English
Standard form for notification of major holdings
Major Shareholding Notification
2023-05-17 English
6-K
Regulatory Filings
2023-05-12 English
Annual General Meeting Poll Results
Declaration of Voting Results & Voting Rights Announcements
2023-05-12 English
Board of Directors and Board Committee Membership
Board/Management Information
2023-05-12 English
6-K
Board/Management Information
2023-05-10 English
Appointment of Independent NED
Board/Management Information
2023-05-10 English
6-K
Declaration of Voting Results & Voting Rights Announcements
2023-04-28 English
Total Voting Rights
Regulatory Filings
2023-04-28 English
6-K
Regulatory Filings
2023-04-21 English
Vesting of awards under the LTIP
Director's Dealing
2023-04-21 English
6-K
Regulatory Filings
2023-04-18 English
NDA Acceptance in China for Fruquintinib
Regulatory Filings
2023-04-18 English
6-K
Regulatory Filings
2023-04-12 English
Presentations at AACR Annual Meeting 2023
Regulatory Filings
2023-04-12 English
6-K
Regulatory Filings
2023-04-11 English
FORM 6-K
Regulatory Filings
2023-04-11 English
Intended Retirement of Independent NED
Board/Management Information
2023-04-11 English
2022 Annual Report and Notice of AGM
Report Publication Announcement
2023-04-11 English
6-K
Regulatory Filings
2023-04-04 English
HUTCHMED Initiates Registration Phase Enrollments
Regulatory Filings
2023-04-04 English
6-K
Regulatory Filings
2023-03-31 English
Total Voting Rights
Regulatory Filings
2023-03-31 English
Rolling Submission of Fruquintinib US NDA Complete
Regulatory Filings
2023-03-31 English
6-K
Regulatory Filings
2023-03-14 English
Closing of Fruquintinib License to Takeda
Regulatory Filings
2023-03-14 English
6-K
Director's Dealing
2023-03-08 English
Director's Share Dealing
Director's Dealing
2023-03-08 English
6-K
Regulatory Filings
2023-03-06 English
Vesting of awards under the LTIP
Director's Dealing
2023-03-06 English
Publication of Form 20-F
Report Publication Announcement
2023-02-28 English
FORM 6-K
Regulatory Filings
2023-02-28 English
FORM 20-F
Annual Report FY 2022
2023-02-28 English
2022 Full Year Results and Business Updates
Earnings Release FY 2022
2023-02-28 English
6-K
Regulatory Filings
2023-02-27 English
Enrollment Completed in Phase 2 Amdizalisib trial
Regulatory Filings
2023-02-27 English
SEC SCHEDULE 13G
Major Shareholding Notification
2023-02-13 English
6-K
Report Publication Announcement
2023-01-31 English
Notice of Results
Report Publication Announcement
2023-01-31 English
6-K
Regulatory Filings
2023-01-23 English
License to Takeda for Fruquintinib outside China
M&A Activity
2023-01-23 English
6-K
Regulatory Filings
2023-01-19 English
Inclusion of ORPATHYS in NRDL in China
Regulatory Filings
2023-01-18 English
6-K
Regulatory Filings
2023-01-03 English
Enrollment Completed in Phase 3 Trial
Regulatory Filings
2023-01-03 English